Additionally, methyl 2-oxo-3-(2-phenylbenzo[d]oxazol-5-yl)propanoate has demonstrated effectiveness in upregulating PGRN protein levels within human cellular models and has shown potential in correcting PGRN protein deficiency in the brains of GRN+/− mice, effectively reversing lysosomal proteome aberrations, a hallmark of FTD [109]. Here, GRN is linked to frontotemporal dementia.